Success Metrics

Clinical Success Rate
83.3%

Based on 395 completed trials

Completion Rate
83%(395/474)
Active Trials
86(13%)
Results Posted
64%(254 trials)
Terminated
79(12%)

Phase Distribution

Ph phase_3
74
11%
Ph early_phase_1
9
1%
Ph phase_4
128
19%
Ph phase_1
115
17%
Ph phase_2
278
42%
Ph not_applicable
35
5%

Phase Distribution

124

Early Stage

278

Mid Stage

202

Late Stage

Phase Distribution639 total trials
Early Phase 1First-in-human
9(1.4%)
Phase 1Safety & dosage
115(18.0%)
Phase 2Efficacy & side effects
278(43.5%)
Phase 3Large-scale testing
74(11.6%)
Phase 4Post-market surveillance
128(20.0%)
N/ANon-phased studies
35(5.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

395 of 508 finished

Non-Completion Rate

22.2%

113 ended early

Currently Active

86

trials recruiting

Total Trials

668

all time

Status Distribution
Active(102)
Completed(395)
Terminated(113)
Other(58)

Detailed Status

Completed395
Terminated79
unknown56
Recruiting49
Active, not recruiting37
Withdrawn34

Development Timeline

Analytics

Development Status

Total Trials
668
Active
86
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 19 (1.4%)
Phase 1115 (18.0%)
Phase 2278 (43.5%)
Phase 374 (11.6%)
Phase 4128 (20.0%)
N/A35 (5.5%)

Trials by Status

not_yet_recruiting112%
completed39559%
suspended20%
terminated7912%
withdrawn345%
recruiting497%
unknown568%
enrolling_by_invitation51%
active_not_recruiting376%

Recent Activity

Clinical Trials (668)

Showing 20 of 668 trialsScroll for more
NCT03816332Phase 1

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Active Not Recruiting
NCT03386539Phase 3

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

Completed
NCT06287944Phase 1

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Recruiting
NCT06120140Phase 2

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Active Not Recruiting
NCT07524530Phase 2

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

Not Yet Recruiting
NCT05457556Phase 3

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Active Not Recruiting
NCT03779854Phase 2

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Recruiting
NCT00792948Phase 2

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT01729494Phase 4

Belatacept Early Steroid Withdrawal Trial

Completed
NCT03712878Phase 2

2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies

Completed
NCT05707377Phase 2

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

Active Not Recruiting
NCT05983770Phase 2

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Completed
NCT06478017Phase 2

Belatacept in Heart Transplantation

Recruiting
NCT06962800Phase 3

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Recruiting
NCT07204275Phase 2

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Recruiting
NCT01861106Phase 2

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

Recruiting
NCT04370301Phase 2

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Recruiting
NCT07709845Phase 2

CC-101 (f/k/a NR1) Neural Stem Cell Transplantation for Adults With Chronic Ischemic Stroke

Not Yet Recruiting
NCT03480360Phase 3

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Completed
NCT04022239Phase 1

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
668